{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T15:22:55Z","timestamp":1789226575021,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T00:00:00Z","timestamp":1715731200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T00:00:00Z","timestamp":1715731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"argenx Japan K.K."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s40120-024-00617-6","type":"journal-article","created":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T12:02:04Z","timestamp":1715774524000},"page":"1099-1113","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Myasthenia Gravis Disease Burden and Its Impact on Satisfaction with Life: A Qualitative Survey of Patients\u2019 Perspectives in Japan"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5779-8429","authenticated-orcid":false,"given":"Naoki","family":"Kawaguchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4790-7301","authenticated-orcid":false,"given":"Koichi","family":"Tsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8058-0816","authenticated-orcid":false,"given":"Nozomu","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6022-109X","authenticated-orcid":false,"given":"Rene","family":"Kerstens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0075-5935","authenticated-orcid":false,"given":"Daisuke","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,15]]},"reference":[{"key":"617_CR1","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1055\/s-0035-1558975","volume":"35","author":"KG Gwathmey","year":"2015","unstructured":"Gwathmey KG, Burns TM. Myasthenia gravis. Semin Neurol. 2015;35:327\u201339.","journal-title":"Semin Neurol"},{"key":"617_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-066445","volume":"13","author":"S Dewilde","year":"2023","unstructured":"Dewilde S, Philips G, Paci S, et al. Patient-reported burden of myasthenia gravis: baseline results of the international prospective, observational, longitudinal real-world digital study MyRealWorld-MG. BMJ Open. 2023;13: e066445.","journal-title":"BMJ Open"},{"key":"617_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0274161","volume":"17","author":"H Yoshikawa","year":"2022","unstructured":"Yoshikawa H, Adachi Y, Nakamura Y, et al. Two-step nationwide epidemiological survey of myasthenia gravis in Japan 2018. PLoS ONE. 2022;17: e0274161.","journal-title":"PLoS ONE"},{"key":"617_CR4","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s40120-022-00408-x","volume":"12","author":"K Jackson","year":"2023","unstructured":"Jackson K, Parthan A, Lauher-Charest M, Broderick L, Law N, Barnett C. Understanding the symptom burden and impact of myasthenia gravis from the patient\u2019s perspective: a qualitative study. Neurol Ther. 2023;12:107\u201328.","journal-title":"Neurol Ther"},{"key":"617_CR5","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","volume":"5","author":"NE Gilhus","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren J. Myasthenia gravis. Nat Rev Dis Primers. 2019;5:30.","journal-title":"Nat Rev Dis Primers"},{"key":"617_CR6","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.nmd.2021.07.396","volume":"31","author":"NE Gilhus","year":"2021","unstructured":"Gilhus NE, Verschuuren J, Hovland SIB, Simmonds H, Groot F, Palace J. Myasthenia gravis: do not forget the patient perspective. Neuromuscul Disord. 2021;31:1287\u201395.","journal-title":"Neuromuscul Disord"},{"key":"617_CR7","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.ncl.2018.01.004","volume":"36","author":"MH Rivner","year":"2018","unstructured":"Rivner MH, Pasnoor M, Dimachkie MM, Barohn RJ, Mei L. Muscle-specific tyrosine kinase and myasthenia gravis owing to other antibodies. Neurol Clin. 2018;36:293\u2013310.","journal-title":"Neurol Clin"},{"key":"617_CR8","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s40120-021-00285-w","volume":"10","author":"N Law","year":"2021","unstructured":"Law N, Davio K, Blunck M, Lobban D, Seddik K. The lived experience of myasthenia gravis: a patient-led analysis. Neurol Ther. 2021;10:1103\u201325.","journal-title":"Neurol Ther"},{"key":"617_CR9","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","volume":"22","author":"V Bril","year":"2023","unstructured":"Bril V, Druzdz A, Grosskreutz J, et al. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study. Lancet Neurol. 2023;22:383\u201394.","journal-title":"Lancet Neurol"},{"key":"617_CR10","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40265-022-01678-3","volume":"82","author":"YA Heo","year":"2022","unstructured":"Heo YA. Efgartigimod: first approval. Drugs. 2022;82:341\u20138.","journal-title":"Drugs"},{"key":"617_CR11","doi-asserted-by":"publisher","first-page":"3862","DOI":"10.1007\/s00415-023-11699-x","volume":"270","author":"A Meisel","year":"2023","unstructured":"Meisel A, Annane D, Vu T, et al. Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension. J Neurol. 2023;270:3862\u201375.","journal-title":"J Neurol"},{"key":"617_CR12","doi-asserted-by":"publisher","first-page":"175628642110019","DOI":"10.1177\/17562864211001995","volume":"14","author":"H Murai","year":"2021","unstructured":"Murai H, Suzuki S, Hasebe M, Fukamizu Y, Rodrigues E, Utsugisawa K. Safety and effectiveness of eculizumab in Japanese patients with generalized myasthenia gravis: interim analysis of post-marketing surveillance. Ther Adv Neurol Disord. 2021;14:17562864211001996.","journal-title":"Ther Adv Neurol Disord"},{"key":"617_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.553626","volume":"11","author":"P Szczudlik","year":"2020","unstructured":"Szczudlik P, Sobieszczuk E, Szyluk B, Lipowska M, Kubiszewska J, Kostera-Pruszczyk A. Determinants of quality of life in myasthenia gravis patients. Front Neurol. 2020;11: 553626.","journal-title":"Front Neurol"},{"key":"617_CR14","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1007\/s00415-021-10891-1","volume":"269","author":"S Lehnerer","year":"2022","unstructured":"Lehnerer S, Jacobi J, Schilling R, et al. Burden of disease in myasthenia gravis: taking the patient\u2019s perspective. J Neurol. 2022;269:3050\u201363.","journal-title":"J Neurol"},{"key":"617_CR15","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1002\/mus.26695","volume":"60","author":"G Cutter","year":"2019","unstructured":"Cutter G, Xin H, Aban I, et al. Cross-sectional analysis of the Myasthenia Gravis Patient Registry: disability and treatment. Muscle Nerve. 2019;60:707\u201315.","journal-title":"Muscle Nerve"},{"key":"617_CR16","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1186\/s12955-020-01549-z","volume":"18","author":"D Dong","year":"2020","unstructured":"Dong D, Chong MKC, Wu Y, et al. Gender differences in quality of life among patients with myasthenia gravis in China. Health Qual Life Outcomes. 2020;18:296.","journal-title":"Health Qual Life Outcomes"},{"key":"617_CR17","doi-asserted-by":"publisher","first-page":"E3","DOI":"10.1097\/JNN.0b013e31828291a6","volume":"45","author":"YT Chen","year":"2013","unstructured":"Chen YT, Shih FJ, Hayter M, Hou CC, Yeh JH. Experiences of living with myasthenia gravis: a qualitative study with Taiwanese people. J Neurosci Nurs. 2013;45:E3-10.","journal-title":"J Neurosci Nurs"},{"key":"617_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0098089","volume":"9","author":"C Barnett","year":"2014","unstructured":"Barnett C, Bril V, Kapral M, Kulkarni A, Davis AM. A conceptual framework for evaluating impairments in myasthenia gravis. PLoS ONE. 2014;9: e98089.","journal-title":"PLoS ONE"},{"key":"617_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-013278","volume":"7","author":"Y Nagane","year":"2017","unstructured":"Nagane Y, Murai H, Imai T, et al. Social disadvantages associated with myasthenia gravis and its treatment: a multicentre cross-sectional study. BMJ Open. 2017;7: e013278.","journal-title":"BMJ Open"},{"key":"617_CR20","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/s12883-016-0757-2","volume":"16","author":"A Frost","year":"2016","unstructured":"Frost A, Svendsen ML, Rahbek J, Stapelfeldt CM, Nielsen CV, Lund T. Labour market participation and sick leave among patients diagnosed with myasthenia gravis in Denmark 1997\u20132011: a Danish nationwide cohort study. BMC Neurol. 2016;16:224.","journal-title":"BMC Neurol"},{"key":"617_CR21","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/1477-7525-8-129","volume":"8","author":"S Twork","year":"2010","unstructured":"Twork S, Wiesmeth S, Klewer J, P\u00f6hlau D, Kugler J. Quality of life and life circumstances in German myasthenia gravis patients. Health Qual Life Outcomes. 2010;8:129.","journal-title":"Health Qual Life Outcomes"},{"key":"617_CR22","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1002\/mus.26694","volume":"60","author":"L Harris","year":"2019","unstructured":"Harris L, Aban IB, Xin H, Cutter G. Employment in refractory myasthenia gravis: a Myasthenia Gravis Foundation of America Registry analysis. Muscle Nerve. 2019;60:700\u20136.","journal-title":"Muscle Nerve"},{"key":"617_CR23","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.jocn.2015.01.022","volume":"22","author":"S Blum","year":"2015","unstructured":"Blum S, Lee D, Gillis D, McEniery DF, Reddel S, McCombe P. Clinical features and impact of myasthenia gravis disease in Australian patients. J Clin Neurosci. 2015;22:1164\u20139.","journal-title":"J Clin Neurosci"},{"key":"617_CR24","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1186\/s12883-019-1573-2","volume":"19","author":"ED Bacci","year":"2019","unstructured":"Bacci ED, Coyne KS, Poon JL, Harris L, Boscoe AN. Understanding side effects of therapy for myasthenia gravis and their impact on daily life. BMC Neurol. 2019;19:335.","journal-title":"BMC Neurol"},{"key":"617_CR25","doi-asserted-by":"publisher","first-page":"3086","DOI":"10.1007\/s00415-021-10902-1","volume":"269","author":"LK Andersen","year":"2022","unstructured":"Andersen LK, Jakobsson AS, Revsbech KL, Vissing J. Causes of symptom dissatisfaction in patients with generalized myasthenia gravis. J Neurol. 2022;269:3086\u201393.","journal-title":"J Neurol"}],"updated-by":[{"DOI":"10.1007\/s40120-024-00639-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:00:00Z","timestamp":1719273600000}}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-024-00617-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-024-00617-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-024-00617-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T06:27:01Z","timestamp":1721629621000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-024-00617-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,15]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["617"],"URL":"https:\/\/doi.org\/10.1007\/s40120-024-00617-6","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40120-024-00639-0","asserted-by":"object"}]},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,15]]},"assertion":[{"value":"18 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised to include the open access license statement.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2024","order":7,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":8,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40120-024-00639-0","URL":"https:\/\/doi.org\/10.1007\/s40120-024-00639-0","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Naoki Kawaguchi has no conflicts of interest to disclose. Rene Kerstens is an employee of argenx. Koichi Tsuda, Nozomu Tanaka, and Daisuke Harada are employees of argenx Japan K.K.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"We did not obtain approval from an ethics committee\/institutional review board, because this survey did not require ethics committee approval for the following reasons: (1) the survey did not involve an investigation of clinical outcomes with any intervention; (2) no identifying information was included in this manuscript; (3) participants were fully informed of the research purpose, provided consent to participate, and agreed for their data to be published; and (4) this survey was approved by argenx.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}